Skip to main content

Table 2 Efficacy of SV2A for the early diagnosis and differential diagnosis of AD

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

 

CSF SV2A

 

Serum SV2A

AUC (95% CI)

p-value

Cutoff (pg/mL)

SEN (%)

SPE (%)

 

AUC (95% CI)

p-value

Cutoff (pg/mL)

SEN (%)

SPE (%)

Con vs. aMCI

0.788 (0.647–0.891)

< 0.0001

≤ 6726.35

100.00

51.43

 

0.741 (0.674–0.802)

< 0.0001

≤ 5050.24

97.80

44.12

Con vs. AD

0.935 (0.857–0.978)

< 0.0001

≤ 4526.64

84.78

94.26

 

0.866 (0.820–0.905)

< 0.0001

≤ 1674.02

66.46

90.20

aMCI vs. AD

0.868 (0.756–0.942)

< 0.0001

≤ 3960.97

76.09

100

 

0.702 (0.642–0.758)

< 0.0001

≤ 1009.39

54.88

80.22

VaD vs. AD

0.905 (0.800–0.966)

< 0.0001

≤ 4526.64

84.78

92.31

 

0.823 (0.764–0.872)

< 0.0001

≤ 1674.02

66.46

83.72

PDD vs. AD

0.918 (0.817–0.974)

< 0.0001

≤ 4526.64

84.78

100.00

 

0.848 (0.790–0.895)

< 0.0001

≤ 1581.51

64.63

93.33

  1. Note: Diagnostic accuracy was evaluated using the receiver operating characteristic (ROC) curve analysis. The Youden index was calculated to determine the best cutoff regarding sensitivity and specificity. Abbreviations: 95% CI, 95% confidence interval; AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AUC, area under the curve; Con, control; CSF, cerebrospinal fluid; PDD, Parkinson’s disease dementia; SEN, sensitivity; SPE, specificity; SV2A, synaptic vesicle glycoprotein 2 A; VaD, vascular dementia
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193